Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Callisto begins treatment in early stage trial
The primary objectives of the phase I clinical trial are to evaluate safety and identify the maximum tolerated dose of L-Annamycin, and to evaluate the antileukemia activity of
The primary objectives of the phase I clinical trial are to evaluate safety and identify the maximum tolerated dose of L-Annamycin, and to evaluate the antileukemia activity of
The supplemental biologics license application (sBLA) contains the results of a phase III study comparing the hemostatic efficacy of Evicel to standard-of-care in retroperitoneal or intra-abdominal surgery in
This phase II study is commencing as a result of initial positive phase II results indicating that the drug known as TPI ASM8 demonstrated protection in early and
Patients treated with 900mg or 300mg per week doses of Riquent had greater reductions in antibodies than placebo or 100mg per week of Riquent. Following eight weeks of
In the phase III trial patients have been randomized into one of three treatment groups: Gabapentin GR once-daily, Gabapentin GR twice-daily and placebo. The company expects to announce
The phase II trial is also designed to determine the extent of its ability to improve the survival of patients with glioblastoma multiforme, the most common form of
CVS issued its statement after Express announced that it was raising its $26.1 billion offer for Caremark, as US regulators requested more information on the hostile bid. Express
Galapagos said it would supply the small molecule compounds to Johnson & Johnson Pharmaceutical research and development division of Janssen Pharmaceutica. The company said the agreement was a
This trial tested an 1800 mg/m2 dose of the drug, AS1404, in combination with carboplatin and paclitaxel chemotherapy. Investigators reported a response rate of 50%. A further 43%
“This represents the first Canadian regulatory approval of a product from Barrier Therapeutics' development pipeline. We anticipate launching Xolegel in Canada in the second half of this year,”